Anebulo Pharmaceuticals, Inc.

NASDAQ:ANEB

1.6 (USD) • At close January 14, 2025
Bedrijfsnaam Anebulo Pharmaceuticals, Inc.
Symbool ANEB
Munteenheid USD
Prijs 1.596
Beurswaarde 41,376,421
Dividendpercentage 0%
52-weken bereik 0.8 - 3.3
Industrie Biotechnology
Sector Healthcare
CEO Dr. Joseph F. Lawler M.D., Ph.D.
Website https://www.anebulo.com

An error occurred while fetching data.

Over Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based

Vergelijkbare Aandelen

HCW Biologics Inc. logo

HCW Biologics Inc.

HCWB

0.342 USD

Minerva Surgical, Inc. logo

Minerva Surgical, Inc.

UTRS

0 USD

TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc.

TCRX

2.63 USD

Galectin Therapeutics Inc. logo

Galectin Therapeutics Inc.

GALT

1.15 USD

Eyenovia, Inc. logo

Eyenovia, Inc.

EYEN

0.086 USD

Centogene N.V. logo

Centogene N.V.

CNTG

0.325 USD

Augmedix, Inc. logo

Augmedix, Inc.

AUGX

2.345 USD

Viracta Therapeutics, Inc. logo

Viracta Therapeutics, Inc.

VIRX

0.17 USD

Financiële Gegevens

Cijfers zijn in miljoenen (USD)

Cijfers zijn in miljoenen (USD)